Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 31 Lung Neoplasms 14 Neoplasms 10 Thoracic Neoplasms 3 Carcinoma 3 Respiratory Tract Neoplasms 2 Respiratory Tract Diseases 2 Neoplasms, Nerve Tissue 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Neoplasm Metastasis 2 NSCLC 2 Meningeal Carcinomatosis 2 Lung Diseases 2 Colorectal Neoplasms 2 Carcinoma, Bronchogenic 2 Bronchial Neoplasms 2 Brain Neoplasms 2 Adenocarcinoma 2 Solid Tumor, Adult 1 Renal Insufficiency 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Noonan Syndrome 1 Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1 Multiple Endocrine Neoplasia Type 2a 1 Mesothelioma, Malignant 1 Lung Cancer Metastatic 1 Lethal Congenital Contracture Syndrome 2 1 Hemangioendothelioma, Epithelioid 1 Head and Neck Neoplasms 1

Interventions

tislelizumab 1 pembrolizumab 1 osimertinib 1 aflutinib 1 Rosuvastatin Calcium 1 RO5126766 1 Midazolam 1 Food 1 Esomeprazole 1 Drug Therapy 1 Docetaxel 1 Dabigatran 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Non-small Cell Lung Cancer × osimertinib × Clear all

NCT05489731 2023-06-15

VIC-1911

Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.

Phase 1 Unknown

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡